InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Newsfile09-30

Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471804620?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TkqaicxTnr1u9ca1ESB2EQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/904b655e613b8bd3ca225d0487908cbf","is_english":true,"pubTime":"2024-09-30 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2471804620","market":"us","top_or_hot":-1,"title":"InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update","media":"Newsfile","content":"<div>\n<p>Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease\nFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular ...</p>\n\n<a href=\"https://finance.yahoo.com/news/inmed-pharmaceuticals-reports-full-fiscal-120000533.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/inmed-pharmaceuticals-reports-full-fiscal-120000533.html><strong>Newsfile</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease\nFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular ...</p>\n\n<a href=\"https://finance.yahoo.com/news/inmed-pharmaceuticals-reports-full-fiscal-120000533.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1242518931.SGD","symbol_name":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/inmed-pharmaceuticals-reports-full-fiscal-120000533.html","article_id":"2471804620","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TkqaicxTnr1u9ca1ESB2EQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/904b655e613b8bd3ca225d0487908cbf"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inmed-pharmaceuticals-reports-full-fiscal-120000533.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2471804620","pubTimestamp":1727697600,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease. Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration. $4.6M revenues in fiscal year 2024, representing a 11% increase over the previous fiscal year. Vancouver, British Columbia-- - InMed Pharmaceuticals Inc.  , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for the fiscal year ending June 30, 2024 and provided a business update on the pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC .The Alzheimer's treatment landscape has shifted significantly in recent years, underscoring the need for innovative, disease-modifying therapies and more convenient treatment options. Industry leaders now recognize that treating a complex diseas","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","BK4512":"苹果概念","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4529":"IDC概念","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU0823421416.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) INC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","BK4007":"制药","BK4566":"资本集团","BK4575":"芯片概念","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","GFS":"GLOBALFOUNDRIES Inc.","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK4588":"碎股","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4141":"半导体产品","INM":"InMed Pharmaceuticals Inc","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","LU0109392836.USD":"富兰克林科技股A","BK4573":"虚拟现实"},"translate_title":"InMed Pharmaceuticals报告2024财年全年财务业绩并提供业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INM":0.9,"GFS":0.9},"content_text":"Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease\nFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration\n$4.6M revenues in fiscal year 2024, representing a 11% increase over the previous fiscal year\n\nVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - InMed Pharmaceuticals Inc. (Nasdaq: INM) (\"InMed\" or the \"Company\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for the fiscal year ending June 30, 2024 and provided a business update on the pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC (\"BayMedica\").\nThe Company's full financial statements and related MD&A for the fiscal year ended June 30, 2024, are available at www.inmedpharma.com and at www.sedar.com.\nFinancial and operating highlights for fiscal 2024:\n\nAs of June 30, 2024, the Company's cash, cash equivalents and short-term investments were $6.6M\nFor the year ended June 30, 2024, the Company recorded a net loss of $7.7M, compared with a net loss of $7.9M for the previous year\nAdvanced INM-901 program with long-term preclinical studies, targeting multiple mechanisms of action in the treatment of Alzheimer's disease\nLaunched INM-089 preclinical program in the treatment of Age-Related Macular Degeneration (\"AMD\") and reported preclinical data demonstrating positive pharmacological effects\nStrengthened patent portfolio with the issuance of three new U.S. patents across formulation and method of use, manufacturing and drug delivery formulation\nTotal sales for BayMedica were $4.6M in fiscal year 2024, representing an 11% increase over the previous fiscal year\n\nEric A. Adams, InMed Chief Executive Officer commented, \"In fiscal year 2024, we made significant progress in our pharmaceutical pipeline, advancing two preclinical programs targeting Alzheimer's disease and dry AMD. Both these programs utilize proprietary small molecule drug candidates that activate both the CB1 and CB2 receptors, as well as other disease-relevant receptors. We are especially encouraged by the rapid advancement of the INM-901 program, which has been in development for less than a year since the drug candidate was selected last October.\"\nThe Alzheimer's treatment landscape has shifted significantly in recent years, underscoring the need for innovative, disease-modifying therapies and more convenient treatment options. Industry leaders now recognize that treating a complex disease like Alzheimer's will likely require a combination of therapies or a multi-faceted approach. With INM-901, InMed has developed an orally available small molecule that has demonstrated disease-modifying effects in preclinical studies by targeting multiple biological pathways, positioning us at the forefront of innovative Alzheimer's research.\"\nBusiness Update\nPharmaceutical Development Programs\nINM-901: Targeting several biological pathways associated with Alzheimer's disease\nINM-901 is a proprietary small molecule drug candidate with multiple mechanisms of action in development as a potential treatment for Alzheimer's disease. Throughout fiscal 2024, the Company announced several key findings for INM-901:\n\nA preferential signaling agonist of the CB1/CB2 receptors and has been shown to have neuroprotective effects, helping protect the neurons in the brain from damage and cell death\nImpacts the peroxisome proliferator-activated receptors (\"PPARs\"), which have been shown to play an important role in diabetes and are also considered as one of the potential therapeutic targets for neurodegenerative disorders such as Alzheimer's disease.\nDemonstrates reduced neuroinflammation and improved neurite growth and neuronal function, indicating the potential to restore damage caused by Alzheimer's disease.\nCan be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal (\"IP\") injection, offering many potential advantages over routes of administration of the currently approved products; and\nDemonstrates significant improvement in cognitive function, memory, locomotor activity, anxiety-based behavior and sound awareness in long term preclinical behavioural studies\n\nInMed continues to accelerate the development of its Alzheimer's program, with additional molecular analysis of a preclinical long-term dosing study currently underway to better define the mechanisms of action. Data read-out is expected in the coming months. Additionally, the development of the chemistry, manufacturing, and controls (\"CMC\") for both the drug substance and the drug product formulation is ongoing, with GLP studies in the planning stages to support an IND submission.\nINM-089: Neuroprotection in the treatment of dry AMD\nINM-089 is a proprietary small molecule drug candidate being studied in the treatment of dry AMD. Throughout fiscal 2024, the Company reported preclinical data for INM-089 demonstrating positive pharmacological effects including. \n\nData indicates that INM-089 may be more effective as a therapeutic treatment for dry AMD compared to neovascular, or wet, AMD\nMore specifically, data suggests INM-089 may be an important candidate for geographic atrophy (\"GA\") which is a more advanced stage of dry AMD\nEnhanced neuroprotection of photoreceptors as well as improved photoreceptor function\nImproved integrity of retinal pigment epithelium\nReduction in extracellular autofluorescent deposits, a hallmark of dry AMD.\n\nINM-755: Dermatology Program - Continuing to seek strategic partnerships \nFurther development of the INM-755 CBN cream is expected to extend beyond its application in Epidermolysis bullosa (\"EB\"), potentially encompassing broader indications related to chronic, severe itch with larger target populations and potential commercial opportunities. InMed continues to assess potential partnership opportunities for the advancement of INM-755. \nContinues to strengthen intellectual property portfolio\nInMed continues to develop its patent portfolio and increase the commercial value of its programs to ensure the long-term protection of our drug research and development efforts. In recent months, InMed has been issued three U.S. patents: one for its formulation and method of use in the treatment of EB and related connective tissue disorders, one for a biosynthesis manufacturing processes and one for an ocular drug delivery formulation.\nBayMedica commercial subsidiary\nBayMedica, a leading supplier of non-intoxicating rare cannabinoids to the health and wellness sector, has experienced sustained revenue growth during the fiscal year 2024, reaching $4.6M, representing an 11% increase over the previous year. Sales and marketing efforts will remain focused on products that contribute highest margins, where BayMedica continues to hold a strong competitive position.\nFinancial commentary:\nFor the year ended June 30, 2024, the Company recorded a net loss of $7.7M, compared with a net loss of $7.9M for the previous year.\nResearch and development and patents expenses were $3.8M for year ended June 30, 2024, compared with $3.7M for the year ended June 30, 2023. However, we expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy. \nThe Company incurred general and administrative expenses of $5.3M for the year ended June 30, 2024, compared to $5.8M in the previous year. The decrease was primarily from a combination of changes in the InMed segment, including lower office and admin fees and investor relations expenses. This was offset by a slight increase in sales and marketing expenses within the BayMedica segment.\nThe Company realized sales of $4.6M in our BayMedica segment for the year ended June 30, 2024, representing an increase of $0.5M, or 11%, for the year ended June 30, 2024, as compared to the year ended June 30, 2023.\nAs of June 30, 2024, we had cash, cash equivalents and short-term investments of $6.6 million The Company expects its cash will be sufficient to fund its planned operating expenses and capital expend to the end of the fourth quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues as well as the level and timing of the Company's operating expenses.\nTable 1. Consolidated Balance Sheet\nInMed Pharmaceuticals Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)Expressed in U.S. Dollars\n\n\n\n\n\n\n\n\n\n\nJune 30,\n\n\nJune 30,\n\n\n\n \n\n2024\n\n\n2023\n\n\n\n\n\n(unaudited)\n\n\n\n\n\n\nASSETS\n\n $ \n\n\n $ \n\n\n\nCurrent\n\n\n\n\n\n\n\n\n    Cash and cash equivalents\n\n6,571,610\n\n\n8,912,517\n\n\n\n    Short-term investments\n\n43,064\n\n\n44,422\n\n\n\n    Accounts receivable (less provision for credit losses of $nil and $66,775 in June 30, 2024 and 2023, respectively)\n\n352,838\n\n\n260,399\n\n\n\n    Inventories, net\n\n1,244,324\n\n\n1,616,356\n\n\n\n    Prepaids and other current assets\n\n477,749\n\n\n498,033\n\n\n\nTotal current assets\n\n8,689,585\n\n\n11,331,727\n\n\n\n\n\n \n\n\n \n\n\n\nNon-Current\n\n \n\n\n \n\n\n\n    Property, equipment and ROU assets, net\n\n1,249,999\n\n\n723,426\n\n\n\n    Intangible assets, net\n\n1,783,198\n\n\n1,946,279\n\n\n\n    Other assets\n\n100,000\n\n\n104,908\n\n\n\nTotal Assets\n\n11,822,782\n\n\n14,106,340\n\n\n\n\n\n \n\n\n \n\n\n\nLIABILITIES AND SHAREHOLDERS' EQUITY\n\n \n\n\n\n\n\n\nCurrent\n\n \n\n\n \n\n\n\n    Accounts payable and accrued liabilities\n\n1,654,011\n\n\n1,608,735\n\n\n\n    Current portion of lease obligations\n\n317,797\n\n\n375,713\n\n\n\n    Deferred rent\n\n-\n\n\n16,171\n\n\n\nTotal current liabilities\n\n1,971,808\n\n\n2,000,619\n\n\n\n\n\n \n\n\n \n\n\n\nNon-current\n\n \n\n\n \n\n\n\n    Lease obligations, net of current portion\n\n644,865\n\n\n15,994\n\n\n\nTotal Liabilities\n\n2,616,673\n\n\n2,016,613\n\n\n\nCommitments and Contingencies (Note 13)\n\n \n\n\n \n\n\n\n\n\n \n\n\n \n\n\n\nShareholders' Equity\n\n \n\n\n \n\n\n\n   Common shares, no par value, unlimited authorized shares: 8,918,956 and \n\n \n\n\n \n\n\n\n3,328,191 as of June 30, 2024 and 2023, respectively, issued and outstanding\n\n82,784,400\n\n\n77,620,252\n\n\n\n   Additional paid-in capital\n\n35,368,899\n\n\n35,741,115\n\n\n\n   Accumulated deficit\n\n(109,075,759\n)\n\n(101,400,209\n)\n\n\n   Accumulated other comprehensive income\n\n128,569\n\n\n128,569\n\n\n\nTotal Shareholders' Equity\n\n9,206,109\n\n\n12,089,727\n\n\n\nTotal Liabilities and Shareholders' Equity\n\n11,822,782\n\n\n14,106,340\n\n\n\nRelated Party Transactions (Note 14)\n\n \n\n\n \n\n\n\n\nTable 2. Consolidated Statements of Operations\nInMed Pharmaceuticals Inc.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)Expressed in U.S. Dollars\n\n\n\n\n\n\n\n\n\nYear Ended\n\n\n\n\n\nJune 30 \n\n\n\n \n\n2024\n\n\n2023\n\n\n\n\n\n $ \n\n\n $ \n\n\n\n\n\n\n\n\n\n\n\n\nSales\n\n4,597,730\n\n\n4,135,561\n\n\n\nCost of sales\n\n3,496,817\n\n\n2,732,525\n\n\n\nGross profit\n\n1,100,913\n\n\n1,403,036\n\n\n\n\n\n \n\n\n \n\n\n\nOperating Expenses\n\n \n\n\n \n\n\n\n    Research and development and patents\n\n3,765,028\n\n\n3,732,056\n\n\n\n    General and administrative\n\n5,250,715\n\n\n5,847,518\n\n\n\n    Amortization and depreciation\n\n219,600\n\n\n202,249\n\n\n\n    Foreign exchange loss\n\n61,921\n\n\n48,175\n\n\n\nTotal operating expenses\n\n9,297,264\n\n\n9,829,998\n\n\n\n\n\n \n\n\n \n\n\n\nOther Income (Expense)\n\n \n\n\n \n\n\n\n    Interest and other income\n\n527,901\n\n\n492,440\n\n\n\nLoss before income taxes\n\n(7,668,450\n)\n\n(7,934,522\n)\n\n\n\n\n \n\n\n \n\n\n\nTax expense\n\n(7,100\n)\n\n(13,100\n)\n\n\nNet loss for the period\n\n(7,675,550\n)\n\n(7,947,622\n)\n\n\n\n\n \n\n\n \n\n\n\nNet loss per share for the period\n\n \n\n\n \n\n\n\n    Basic and diluted\n\n(1.01\n)\n\n(3.25\n)\n\n\nWeighted average outstanding common shares\n\n \n\n\n \n\n\n\n    Basic and diluted\n\n7,621,075\n\n\n2,448,458\n\n\n\n\nTable 3. Consolidated Statements of Cash Flows\nInMed Pharmaceuticals Inc.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)For the year ended June 30, 2024 and 2023Expressed in U.S. Dollars\n\n\n\n\n\n\n\n\n\n \n\nJune 30, 2024\n\n\nJune 30, 2023\n\n\n\n\n\n\n\n\n\n\n\n\nCash provided by (used in):\n\n $ \n\n\n $ \n\n\n\n\n\n\n\n\n\n\n\n\nOperating Activities\n\n\n\n\n\n\n\n\nNet loss\n\n              (7,675,550)\n\n\n              (7,947,622)\n\n\n\nItems not requiring cash:\n\n\n\n\n\n\n\n\n    Amortization and depreciation\n\n219,600\n\n\n202,249\n\n\n\n    Share-based compensation\n\n137,714\n\n\n278,155\n\n\n\n    Amortization of right-of-use assets\n\n384,918\n\n\n393,748\n\n\n\n    Interest income received on short-term investments\n\n(1,250\n)\n\n(803\n)\n\n\n    Unrealized foreign exchange loss\n\n12,262\n\n\n1,183\n\n\n\n    Inventory write-down\n\n305,812\n\n\n308,937\n\n\n\n    Credit losses\n\n-\n\n\n46,775\n\n\n\nChanges in operating assets and liabilities:\n\n \n\n\n \n\n\n\n    Inventories\n\n66,220\n\n\n565,561\n\n\n\n    Prepaids and other currents assets\n\n20,284\n\n\n299,192\n\n\n\n    Other non-current assets\n\n4,908\n\n\n5,507\n\n\n\n    Accounts receivable\n\n(92,439\n)\n\n(219,147\n)\n\n\n    Accounts payable and accrued liabilities\n\n45,282\n\n\n(806,530\n)\n\n\n    Deferred rent\n\n(16,171\n)\n\n16,171\n\n\n\n    Lease obligations\n\n(397,422\n)\n\n(426,575\n)\n\n\nTotal cash used in operating activities\n\n(6,985,832\n)\n\n(7,283,199\n)\n\n\n\n\n \n\n\n \n\n\n\nInvesting Activities\n\n \n\n\n \n\n\n\n    Payment of acquisition consideration\n\n-\n\n\n(500,000\n)\n\n\n    Payment of deposit on equipment\n\n-\n\n\n(1,790\n)\n\n\n    Sale of short-term investments\n\n42,082\n\n\n42,268\n\n\n\n    Purchase of short-term investments\n\n(42,082\n)\n\n(42,268\n)\n\n\n    Purchase of property and equipment\n\n(9,293\n)\n\n(160,014\n)\n\n\nTotal cash (used in) provided by investing activities\n\n(9,293\n)\n\n(661,804\n)\n\n\n\n\n \n\n\n \n\n\n\nFinancing Activities\n\n \n\n\n \n\n\n\nShares issued for cash\n\n \n\n\n \n\n\n\nshare issuance costs\n\n \n\n\n \n\n\n\nProceeds from the exercise of pre-funded warrants\n\n175\n\n\n646\n\n\n\nProceeds from private placement net of issuance costs\n\n4,654,043\n\n\n10,680,008\n\n\n\nTotal cash provided by financing activities\n\n4,654,218\n\n\n10,680,654\n\n\n\n\n\n \n\n\n \n\n\n\nIncrease in cash during the period\n\n(2,340,907\n)\n\n2,735,649\n\n\n\nCash and cash equivalents beginning of the period\n\n8,912,517\n\n\n6,176,866\n\n\n\nCash and cash equivalents end of the period\n\n6,571,610\n\n\n8,912,515\n\n\n\n\n\n \n\n\n \n\n\n\nSUPPLEMENTARY CASH FLOW INFORMATION:\n\n \n\n\n \n\n\n\nCash Paid During the Year for:\n\n \n\n\n \n\n\n\n    Income taxes\n$\n-\n\n$\n-\n\n\n\n    Interest\n$\n-\n\n$\n-\n\n\n\n\n\n \n\n\n \n\n\n\nSUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:\n\n \n\n\n \n\n\n\nFair value of warrant modification recorded as equity issuance costs\n$\n3,508,749\n\n$\n-\n\n\n\n    Preferred investment options to its placement agent\n$\n325,699\n\n$\n691,483\n\n\n\n    Recognition of Right-of-use asset and corresponding operating lease liability\n$\n968,376\n\n$\n-\n\n\n\n\nAbout InMed\nInMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three drug development programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com.\n\nInvestor Contact: \nColin ClancyVice President, Investor Relationsand Corporate CommunicationsT: +1.604.416.0999E: cclancy@inmedpharma.com\n\nCautionary Note Regarding Forward-Looking Information: \nThis news release contains \"forward-looking information\" and \"forward-looking statements\" (collectively, \"forward-looking information\") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: expecting revenue fluctuations based on distributor order patterns; remaining optimistic about the long-term growth potential in the rare cannabinoids sector as the business dynamics and commercial opportunities continue to mature; advancing our pharmaceutical pipeline using rare cannabinoids for potential therapeutic applications in dermatology, ocular and neurodegenerative disease; the efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed's Alzheimer's program; the efficacy of INM-089, INM-089's ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed's AMD program; further development and commercial uses of the INM-755; expectations that the Company's cash will be sufficient to fund its planned operating expenses and capital expenditure requirements to the end of the fourth quarter of calendar year 2024.\nAdditionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.\nAll forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.\n\nTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/224716","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471804620"}